Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02).
Klaeser B, Nitzsche E, Schuller JC, Köberle D, Widmer L, Balmer-Majno S, Hany T, Cescato-Wenger C, Brauchli P, Zünd M, Pestalozzi BC, Caspar C, Albrecht S, von Moos R, Ruhstaller T. Klaeser B, et al. Among authors: pestalozzi bc. Onkologie. 2009 Dec;32(12):724-30. doi: 10.1159/000251842. Epub 2009 Nov 9. Onkologie. 2009. PMID: 20016233 Clinical Trial.
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Ribi K, Koeberle D, Schuller JC, Honegger H, Roth A, Hess V, Moosmann P, von Moos R, Borner M, Lombriser N, Pestalozzi B, Ruhstaller T. Ribi K, et al. Support Care Cancer. 2009 Aug;17(8):1109-16. doi: 10.1007/s00520-008-0570-6. Epub 2009 Feb 7. Support Care Cancer. 2009. PMID: 19198893 Free article. Clinical Trial.
Changing PET/CT manifestation of neurolymphomatosis.
Strobel K, Pestalozzi B, Ciernik I, Schaefer NG, Koma AY, Hany TF. Strobel K, et al. Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1244. doi: 10.1007/s00259-006-0112-8. Epub 2006 Jul 6. Eur J Nucl Med Mol Imaging. 2006. PMID: 16823555 Free article. No abstract available.
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).
Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK). Pestalozzi BC, et al. BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1. BMC Cancer. 2017. PMID: 28407750 Free PMC article.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T. Schmid S, et al. BMC Cancer. 2019 Sep 10;19(1):902. doi: 10.1186/s12885-019-6105-3. BMC Cancer. 2019. PMID: 31500588 Free PMC article. Clinical Trial.
139 results